BPMUF Stock Chart & Stats
$77.58
-$4.83(-7.41%)
At close: 4:00 PM EDT
$77.58
-$4.83(-7.41%)
Day’s Range― - ―
52-Week Range$48.35 - $85.95
Previous CloseN/A
Volume12.00
Average Volume (3M)3.00
Market Cap
$975.55M
Enterprise Value$644.92
Total Cash (Recent Filing)$175.98M
Total Debt (Recent Filing)$83.44M
Price to Earnings (P/E)15.0
Beta0.02
Next Earnings
Feb 16, 2027EPS Estimate
3.1Next Dividend Ex-DateN/A
Dividend Yield4.02%
Share Statistics
EPS (TTM)4.26
Shares Outstanding13,440,478
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)5.22
Price to Sales (P/S)2.88
P/FCF Ratio11.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.73
Revenue Forecast (FY)$325.23M
Bulls Say, Bears Say
Bulls Say
Commercial Growth And Product DemandStrong Cresemba demand supports a growing royalty and product-revenue base. Continued commercial adoption of marketed anti-infectives can improve revenue visibility and provide funding for pipeline development over the medium term.
Cash Generation And Balance Sheet ImprovementPositive operating and free cash flow, alongside a shift to net cash, reduces reliance on external financing. This strengthens Basilea’s ability to fund clinical programs, absorb setbacks and support commercialization without immediate dilution.
Funded Anti-Infective PipelineSubstantial nondilutive funding lowers the company’s development burden and extends runway for late-stage programs. Progress in fosmanogepix and ceftibuten-ledaborbactam could broaden the portfolio beyond current marketed products.
Bears Say
Volatile ProfitabilityThe margin decline indicates that earnings remain sensitive to product mix, milestones and other variable items. High gross margins are encouraging, but inconsistent conversion into net profit makes medium-term earnings quality less predictable.
Clinical And Regulatory Execution RiskLate-stage programs require successful trials, regulatory alignment and timely filings before they can generate revenue. Delayed readouts or additional study requirements could extend development costs and postpone portfolio diversification.
Partner And Financing DependenceReliance on partners for regional commercialization limits Basilea’s control over supply and market execution. The remaining convertible maturity also creates a financing obligation that could constrain flexibility if operating performance weakens.
Basilea Pharmaceutica News
BPMUF FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was $48.35 and its highest was $85.95 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is $975.55M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Feb 16, 2027 which is in 160 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Aug 18, 2026. The company reported $2.662 earnings per share for the quarter, missing the consensus estimate of $4.178 by -$1.516.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Overvalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a Annually dividend of $5.38 which represents an annual dividend yield of 4.02%. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 3.1.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,440,478 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of $2.662 in its last earnings report, missing expectations of $4.178. Following the earnings report the stock price went up 8.415%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in BPMUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
Technical Analysis
Molecular Partners AG
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
MindMaze Therapeutics Holding SA
―
Ownership Overview
―
Insiders
3.56% Mutual Funds
0.11% Other Institutional Investors
83.95% Public Companies and
Individual Investors